Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Former J&J senior exec joins board of Advanced Cardiac Therapeutics

This article was originally published in Clinica

Executive Summary

Roy Tanaka, former president of Johnson & Johnson's Biosense Webster division, has been elected to the board of directors at cardiac ablation system developer Advanced Cardiac Therapeutics (ACT). Mr Tanaka joined Biosense Webster, which specialises in technologies for treating cardiac arrhythmias, as US president in 1997. He then served as worldwide president from 2004-2008. He has also held senior management roles at Sorin Biomedical, CooperVision Surgical and Pfizer-subsidiary Shiley. Laguna Beach, California-based ACT has developed the TEMPASURE cardiac ablation catheter for treating atrial fibrillation. It is said to be the world’s first temperature-sensing cardiac ablation catheter; the technology was first developed to spy on Soviet crop growth. ACT raised $5m in series B financing earlier this year and initiated its first-in-man trial in March.

You may also be interested in...

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts